Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

John Q Trojanowski

Showing results (1-10 of 886) with videos related to

Pageof 89
Sort By:
Experimental Neurology|December 31, 2002
Rotenone neurotoxicity: a new window on environmental causes of Parkinson's disease and related brain amyloidosesJohn Q Trojanowski
The American Journal of Pathology|February 13, 2002
Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discoveryJohn Q Trojanowski
Annals of Neurology|September 3, 2002
Tauists, Baptists, Syners, Apostates, and new dataJohn Q Trojanowski
Neurobiology of Aging|December 10, 2002
"Emerging Alzheimer's disease therapies: focusing on the future"John Q Trojanowski
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 11, 2004
Protein mis-folding emerges as a "drugable" target for discovery of novel therapies for neuropsychiatric diseases of agingJohn Q Trojanowski
Neuro-Signals|December 22, 2007
PENN neurodegenerative disease research - in the spirit of Benjamin FranklinJohn Q Trojanowski
Progress in Neurobiology|August 9, 2011
Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and interventionJohn Q Trojanowski, Harald Hampel
JAMA|July 23, 2009
Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practiceRonald C Petersen, John Q Trojanowski
The Lancet. Neurology|June 19, 2012
Primary or secondary prevention for AD: who cares?Giovanni B Frisoni, John Q Trojanowski
Neuromolecular Medicine|October 7, 2003
Overview of protein aggregation in single, double, and triple neurodegenerative brain amyloidosesJohn Q Trojanowski, Mark P Mattson
Pageof 89

Showing results (1-10 of 886) with videos related to

Sort By:
Pageof 89
Experimental Neurology|December 31, 2002
Rotenone neurotoxicity: a new window on environmental causes of Parkinson's disease and related brain amyloidosesJohn Q Trojanowski
The American Journal of Pathology|February 13, 2002
Neuropathological verisimilitude in animal models of Alzheimer's disease: key to elucidating neurodegenerative pathways and identifying new targets for drug discoveryJohn Q Trojanowski
Annals of Neurology|September 3, 2002
Tauists, Baptists, Syners, Apostates, and new dataJohn Q Trojanowski
Neurobiology of Aging|December 10, 2002
"Emerging Alzheimer's disease therapies: focusing on the future"John Q Trojanowski
The American Journal of Geriatric Psychiatry : Official Journal of the American Association for Geriatric Psychiatry|March 11, 2004
Protein mis-folding emerges as a "drugable" target for discovery of novel therapies for neuropsychiatric diseases of agingJohn Q Trojanowski
Neuro-Signals|December 22, 2007
PENN neurodegenerative disease research - in the spirit of Benjamin FranklinJohn Q Trojanowski
Progress in Neurobiology|August 9, 2011
Neurodegenerative disease biomarkers: guideposts for disease prevention through early diagnosis and interventionJohn Q Trojanowski, Harald Hampel
JAMA|July 23, 2009
Use of Alzheimer disease biomarkers: potentially yes for clinical trials but not yet for clinical practiceRonald C Petersen, John Q Trojanowski
The Lancet. Neurology|June 19, 2012
Primary or secondary prevention for AD: who cares?Giovanni B Frisoni, John Q Trojanowski
Neuromolecular Medicine|October 7, 2003
Overview of protein aggregation in single, double, and triple neurodegenerative brain amyloidosesJohn Q Trojanowski, Mark P Mattson
Pageof 89